What is the concentration per milliliter when 36 mg of retatrutide is reconstituted in 360 mL of bacteriostatic water?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Retatrutide Reconstitution Concentration

When reconstituting 36 mg of retatrutide in 360 mL of bacteriostatic water, the final concentration is 0.1 mg/mL.

Calculation Method

The concentration calculation follows basic pharmaceutical dilution principles:

  • Concentration = Total drug amount ÷ Total volume
  • 36 mg ÷ 360 mL = 0.1 mg/mL 1

Practical Considerations for This Dilution

Volume and Stability Concerns

  • This represents an extremely high dilution ratio (1:10 ratio of standard reconstitution practices), which may compromise drug stability 1
  • Standard reconstitution guidelines recommend against over-dilution, as it can jeopardize stability and necessitate impractically large injection volumes 1
  • Reconstituted peptide solutions have limited stability and should not be retained long-term unless specific stability data support extended use 1, 2

Storage and Handling

  • Store the reconstituted solution at 2-8°C (36-46°F) 1
  • Bacteriostatic water contains approximately 0.9% benzyl alcohol preservative, permitting multi-dose use for up to 28 days when refrigerated 1
  • Label the vial with concentration (0.1 mg/mL), reconstitution date, and beyond-use date 1
  • Discard if the solution becomes discolored or contains particulate matter 1

Clinical Context

  • Retatrutide clinical trials used doses ranging from 1 mg to 12 mg weekly for obesity and type 2 diabetes 3, 4
  • At 0.1 mg/mL concentration, administering even a 1 mg dose would require 10 mL injection volume, which is impractical for subcutaneous administration 1
  • Standard subcutaneous injection volumes should not exceed 1-2 mL per site 1

Common Pitfalls to Avoid

  • Never use sterile water without preservative for multi-dose vials, as this raises contamination risk 1
  • Do not reconstitute powder that has been exposed to moisture or appears discolored prior to mixing 1
  • Maintain strict aseptic technique: sanitize vial stopper with 70% isopropanol, inject diluent slowly down the vial side, and gently swirl (do not shake vigorously) 1
  • Perform visual inspection after mixing for clarity and absence of particulate matter 1

References

Guideline

NAD+ Reconstitution Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Ertapenem Dosing for Contaminated Colon Surgery

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Do retatrutide (reta) and survodutide increase dopamine levels?
Does retatrutide have less muscle loss compared to other treatments?
Does retatrutide (tirzepatide) retain muscle better than Ozempic (semaglutide)?
Can a reconstituted mixture of Retratutide be reused?
Is the dosing of retatrutide determined by the patient’s body weight?
Is it safe to combine Keppra (levetiracetam) with Dilantin (phenytoin) in an adult patient with normal renal function and no severe hepatic disease?
In an adult with end‑stage heart failure being evaluated for cardiac transplantation, should a comprehensive transthoracic echocardiogram with Doppler and tissue‑Doppler measurements be performed as part of the pre‑transplant work‑up?
A patient with an estimated glomerular filtration rate (eGFR) of 43 mL/min/1.73 m²—what chronic kidney disease (CKD) stage does this correspond to and what immediate evaluation and management steps are indicated?
Is systemic or topical heparinoid therapy appropriate for managing an acute hematoma in a patient on anticoagulation for atrial fibrillation or deep‑vein thrombosis?
Can I prescribe daily polyethylene glycol 3350 (MiraLAX) to an elderly patient already taking linaclotide (Linzess) for constipation?
What is the recommended fosfomycin tromethamine dosing for an adult with uncomplicated urinary tract infection, and how should the regimen be modified for recurrent infection, multidrug‑resistant organisms, complicated cystitis, severe renal impairment, and pregnancy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.